Difference between revisions of "TRK fusions"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
*The TRK genes are tyrosine kinase receptors. | *The TRK genes are tyrosine kinase receptors. | ||
*Multiple fusion partners for each gene. | *Multiple fusion partners for each gene. | ||
*Testing: RNA-based next generation sequencing. | |||
==Classic associations== | ==Classic associations== | ||
Revision as of 05:47, 11 September 2018
TRK fusions are seen in many solid tumours and have targeted drugs.
General
Genes
- TRK1.
- TRK2.
- TRK3.
Notes:
- The TRK genes are tyrosine kinase receptors.
- Multiple fusion partners for each gene.
- Testing: RNA-based next generation sequencing.
Classic associations
- Mammary analogue secretory carcinoma (MASC) - ETV6-NTRK3.[1]
- Secretory breast carcinoma - ETV6-NTRK3.[2]
Drugs
- Merestinib.
- Larotrectinib.
- Others.
See also
References
- ↑ Lei, Y.; Chiosea, SI. (Jun 2012). "Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.". Head Neck Pathol 6 (2): 166-70. doi:10.1007/s12105-011-0312-9. PMID 22127547.
- ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.